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Abstract
Introduction: Previously, we demonstrated that children with active systemic vasculitis (SV) have higher circulating
CD34 + CD133 + KDR+ endothelial progenitor cells (EPC); the function of these EPCs, and their relationship with disease
activity in vasculitis remains largely unexplored. We hypothesized that although EPC numbers are higher, EPC function
is impaired in active SV of the young. The aims of this study were therefore to: 1. investigate the relationship between
disease activity and EPC function in children with SV; and 2. study the influence of systemic inflammation on EPC
function by investigating the effects of hyperthermia and TNF-α on EPC function.
Methods: We performed a cross-sectional study of unselected children with SV with different levels of disease activity
attending a single center (Great Ormond Street Hospital, London) between October 2008 and December 2014. EPCs
were isolated from peripheral blood of children with SV, and healthy child controls. EPC function was assessed by their
potential to form colonies (EPC-CFU), and ability to form clusters and incorporate into human umbilical vein endothelial
cell (HUVEC) vascular structures in matrigel. The effects of hyperthermia and TNF-α on EPC function were also studied.
Results: Twenty children, median age 12-years (5–16.5; nine males) were studied. EPC-CFU and the number of EPC
clusters formed on matrigel were significantly reduced in children with active vasculitis compared with healthy controls
(p = 0.02 for EPC-CFU; p = 0.01 for EPC cluster formation). Those with active vasculitis had lower EPC-CFU and EPC cluster
formation than those with inactive disease, although non-significantly so. In addition, EPC incorporation into matrigel
HUVEC networks was lower in children with SV compared with healthy children, irrespective of disease activity. Ex-vivo
pre-treatment of EPC with hyperthermia impaired EPC function; TNF-α down-regulated EPC expression of CD18/CD11b
and resulted in decreased incorporation into HUVEC networks.
Conclusions: Whilst our previous work showed that circulating CD34 + EPC numbers are well preserved, this study
revealed that EPC function is significantly impaired in children with vasculitis. It is possible that the chronic
inflammatory milieu associated with vasculitis may impair EPC function, and thus contribute to an unfavourable
balance between endothelial injury and repair. The mechanism of this remains to be established, however.
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Introduction
Systemic vasculitis (SV) of the young is characterised by
systemic inflammation, endothelial activation, and (in some
cases) necrosis of blood vessel walls leading to multi-organ
injury [1, 2]. Endothelial activation and injury are central to
the pathogenesis of SV with increased endothelial cell ad-
hesion molecule expression, and a switch to a prothrombo-
tic endothelial phenotype, both of which contribute to the
vascular pathology of SV [3, 4]. In addition to this severe
endothelial injury, it has been suggested that endothelial
repair processes may also be impaired [5, 6], and thus SV
could be particularly damaging to the cardiovascular sys-
tem due to an unfavourable imbalance between endothelial
injury and repair, as is the case in other diseases targeting
the endothelium [7, 8].
It is now known that recruitment of bone marrow-
derived endothelial progenitor cells (EPC) represents an
important mechanism of endothelial repair [9]. These
EPCs may play an important role in endothelial main-
tenance and vascular healing in health and disease, and
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are emerging as important biomarkers of prognosis in ath-
erosclerosis [10, 11]. Previous studies have employed two
main methods to study EPCs in humans: 1) flow cytometric
quantification of circulating CD34+ haematopoietic pro-
genitors, usually co-expressing additional surface markers
including CD133 and/or vascular endothelial growth factor
receptor 2 (VEGFR2) [12]; and 2) quantification of circulat-
ing myeloid-derived EPC colony forming units (EPC-CFU)
in angiogenic medium [12]. Little is known, however, about
the impact of SV on these repair processes, despite con-
cerns that vascular dysfunction is an important late seque-
lae of vasculitis in children [13, 14] and adults [15].
We have previously postulated that there is an un-
favourable balance between endothelial injury and repair
in children with SV [16], and that aging and dyslipidaemia
also influence this balance [17]. We previously demon-
strated evidence of excessive endothelial injury in children
with SV: elevated numbers of circulating endothelial cells
(CECs) [16], and increased circulating endothelial micro-
particles (EMPs) [16, 18]. It is possible that children
mount an attempted adaptive response to this excessive
endothelial injury, since we also observed increased circu-
lating CD34 + CD133 + VEGFR2 + EPCs using flow cyto-
metric analysis of peripheral blood monocytes in children
with active vasculitis [16]. The functional relevance of this
possible adaptive haematopoietic EPC response in paediat-
ric SV has not yet been established, however. In the light
of our previous findings, we hypothesised that the signifi-
cant inflammatory milieu associated with SV would ad-
versely affect EPC function, resulting in defective colony
formation, adhesion and ability to integrate into vascular
networks. The aims of the current study, therefore, were
to: 1) investigate the relationship between disease activity
and EPC function in children with SV; and 2) to study the
potential influence of systemic inflammation on EPC
function by investigating the effects of hyperthermia and
TNF-α on EPC function in vitro.
Methods
Patients and controls
We performed a cross-sectional study of unselected chil-
dren with SV with different levels of disease activity at-
tending a single center (Great Ormond Street Hospital
NHS Foundation Trust, London) between October 2008
and December 2014. Parental consent was obtained for all
children involved in the study, which was approved by the
Institutional Ethics Committee (see acknowledgements
for details). Inclusion criteria for children with SV were as
follows: age <18 years, a diagnosis of SV confirmed by his-
topathologic and/or arteriographic assessment, and sec-
ondary causes of vasculitis excluded (infection, other
connective tissue disease, or malignancy). Control samples
were obtained from healthy sex- and age-similar children;
adult healthy controls were members of staff within our
laboratory (median age 33 years, range 22–35 years; one
female). All participating subjects provided written, fully-
informed consent.
Vasculitis subtype was classified using the EULAR/
PRINTO/PReS classification criteria for paediatric vasculit-
ides [19] for: polyarteritis nodosa (PAN), granulomatosis
with polyangiitis (GPA, formerly Wegener’s granulomato-
sis), and Takayasu arteritis (TA). Kawasaki disease (KD)
was defined as patients fulfilling at least five of six of the
American Heart Association criteria for KD [20]. Micro-
scopic polyangiitis (MPA) was defined according to the
Chapel Hill definitions [21]. Patients with Behçet’s disease
(BD) fulfilled the International Study Group for Behçet’s
Disease criteria [22]. Disease activity was assessed using the
Paediatric Vasculitis Activity Score (PVAS) [16, 19, 23, 24]
which is shown in detail in Additional file 1 (Paediatric
Vasculitis Activity Score) and Additional file 2 (glossary
and scoring for PVAS). Active vasculitis was defined as a
score greater than zero for PVAS items attributable to vas-
culitis that newly appeared or worsened during the preced-
ing four weeks, and for which other causes such as
infection were excluded [16, 24]. Patients in remission had
a PVAS of 0/63. Routine laboratory markers [erythrocyte
sedimentation rate (ESR) normal range 0–10 mm/h, and
C-reactive protein (CRP) normal range < 20 mg/L] levels
provided adjunctive information regarding systemic inflam-
mation related to systemic vasculitis activity.
Immunomagnetic bead extraction of circulating
endothelial cells from peripheral blood
CECs were extracted from whole blood using CD146-
coated immunomagnetic beads using an international
consensus protocol [25, 26]. CECs extracted in this way
were counted using a Nageotte chamber on a fluorescence
microscope and were defined as Ulex europaeus lectin
(Sigma-Aldrich, Doset, UK) bright cells that were > 10 μm
in size, with five or more magnetic beads attached.
Functional assay of endothelial progenitor cells
Endothelial progenitor cell colony-forming units
EPC-CFUs were cultured with slight modification from
methods previously described [9, 27]. Briefly, peripheral
blood mononuclear cells (PBMC) were isolated by dens-
ity centrifugation (Lymphoprep TM, Axis Shield, Dun-
dee, UK). After purification with three washing steps,
2 × 106 PBMCs were plated on fibronectin-coated 24-
well plates. Cells were cultured and maintained in endo-
thelial growth media (EGM-2) culture medium supple-
mented with growth factors according to the
manufacturer’s recommendations (PromoCell, Heidelberg,
Germany), plus 20 % foetal calf serum (FCS) and 40 ng/ml
of vascular endothelial growth factor (VEGF). After four
days of culture, non-adherent cells were removed by
washing with phosphate buffered saline (PBS). In some
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experiments TNF-α (10–50 ng/ml) was added to the
media. Culture medium was changed to maintain the cells
in culture until day 7. The numbers of myeloid-EPC col-
ony forming units (EPC-CFU), characterized by a cluster
of cells surrounded by elongated spindled-shaped cells,
were counted manually in a minimum of two wells in 24-
well plates by two independent observers who were un-
aware of the clinical profiles of the patients from whom
the cells were derived. Results were expressed as average
number of EPC-CFUs per well. Fig. 1a shows a represen-
tative EPC-CFU on day 7 from EPCs isolated from a five-
year-old healthy control child. In selected samples, uptake
of Di-I-acetylated low-density lipoprotein (Di-IAcLDL,
Invitrogen, Paisley, UK) was confirmed, in line with other
studies of this nature [10, 27].
Matrigel assays: EPC cluster formation and incorporation
assays
Matrigel assays were employed to examine the ability of
EPC to incorporate into endothelial capillary networks
(hereafter referred to as the EPC-incorporation assay)
[28] and the ability of EPC to form clusters (clusters of
more than ten cells), a measure of EPC sprout formation
(hereafter referred to as the EPC-cluster formation
assay) [29]. Human umbilical vein endothelial cells
(HUVEC; PromoCell) were cultured in EGM-2 medium
supplemented with 2 % FCS, hydrocortisone, fibroblast
growth factor (FGF-2), VEGF, R3-insulin-like growth
factor-1, epidermal growth factor, heparin, ascorbic acid,
gentamycin and amphotericin B, as supplied by the manu-
facturer (PromoCell) at 37 °C in 5 % CO2 in a humidified
incubator. HUVECs at 80 % confluency (passages 2–4)
were used for experiments. Growth factor reduced Matrigel
Matrix (Becton Dickinson Labware, Oxford, UK) was
thawed and placed in 96-well plates at 37 °C for 30 min to
solidify. EPCs were labeled with 2 μg/ml of Di-I-LDL to dis-
tinguish them from HUVECs.
For the EPC-cluster formation assay, 10,000 EPCs were
plated in Matrigel; for the EPC-incorporation assay, DiI-
labeled EPCs (3,000/well) were co-plated with HUVEC
(10,000/well) on top of a solidified Matrigel layer and cul-
tured at 37 °C for 18–20 h with EGM-2 medium.
Incorporation of EPC into capillary networks of HUVEC
on Matrigel or EPC cluster formation was then examined
with fluorescence microscopy. Five independent fields
were assessed for each well and the mean numbers of
EPCs incorporated into the HUVEC capillary networks
and EPC clusters/x 100 fields were determined.
Effects of TNF-α and hyperthermia on EPC adhesion and
incorporation into HUVEC networks
EPC adhesion assay
EPC adhesion to fibronectin and HUVECs was assessed.
EPCs were labeled with Di-I-LDL and 1 × 105 cells were
placed on fibronectin-coated 96-well plates or on a mono-
layer of HUVECs pretreated with TNF-α (50 ng/ml) for
six h, and incubated for one h at 37 °C. Non-attached cells
were gently removed by washing with PBS, and adherent
EPCs were fixed with 4 % paraformaldehyde and counted
in ten random fields.
XXT assay of cell viability in response to hyperthermia
Cell viability under different experimental conditions was
determined by XTT (xylin tetrazolium) assay, which is
Fig. 1 Reduced endothelial progenitor cell-colony forming units (EPC-CFU) in children with active systematic vasculitis. a Representative image of
EPC-colony forming unit (EPC-CFU from a healthy control child). b Comparison of EPC-CFU in children with active and inactive systematic vasculitis
and child healthy controls. EPC-colony forming EPC-CFUs were reduced in 15 children with active disease compared to healthy control children but
not in five children with inactive disease compared to healthy child controls (p = 0.3). The Kruskal-Wallis test was used to examine overall differences
between the study groups followed by the Mann–Whitney U test. P values < 0.05 were considered significant
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based on the ability of metabolically active cells to reduce
the tetrazolium salt XTT to orange coloured compounds
of formazan. EPC or HUVEC (1 × 104) were plated into
96-well plates in EGM-2. After 24 h at 37 °C, cells were in-
cubated at 39 °C for 2, 4, 18 h, then replaced in a 37 °C in-
cubator for up to 18 h of total culture time. XTT was
added to the culture medium and incubated at 37 °C for
four h. The formazan product was read at a wavelength of
545 nm with reference wavelength at 690 nm.
Statistical analysis
All in vitro experiments were performed in triplicate un-
less otherwise stated, and values are presented as mean ±
standard error of the mean unless otherwise specified.
Statistical differences for in vitro experiments between
groups were determined by two-way analysis of variance
(ANOVA), followed by unpaired two-tailed T-test. Patient
demographics are summarized as median and range. The
Kruskal-Wallis test was used to examine overall dif-
ferences between the study groups followed by the
Mann–Whitney U test. P-values of less than 0.05 were
regarded as significant. All analysis was performed using
SPSS version 22.
Results
Patients and controls
We studied 20 unselected consecutive patients with a diag-
nosis of SV; the median age at time of study was 12.0
(range 9.0–16.5) years; six patients were male. There were
five paediatric healthy controls (two male, three female) of
median age four years (range, 3.6-10 years). Fifteen children
had active SV (n = 8 PAN; n = 4 GPA; n = 1 EGPA; n = 1
KD; n = 1 unclassified but biopsy proven SV), with median
PVAS of 4/63 (range 4–26/63); five children had inactive
SV (n = 4 with GPA; and n = 1 Behçet’s disease) with a
PVAS of 0/63 in all. The clinical features of the vasculitis
patients are summarized in Table 1. Median follow up for
those with active disease was nine months (6–36 months);
median follow up for those with inactive disease was 12
months (6–24 months).
Patients with clinically active vasculitis had evidence of
endothelial injury, with an increased median CEC count
of 88 (8–420) cells/ml, and systemic inflammation as indi-
cated by a median ESR of 73 (11–137) mm/h and a CRP
of 18.5 (5–270) mg/L; for children with inactive disease
median CEC count was 16 (0–40) cells/ml, median ESR
was 3 (3–37) mm/h, and median CRP was 5 (5–16) mg/L.
For healthy controls there was a median CEC count of 24
(0–80) cells/ml; these healthy paediatric controls did not
have CRP or ESR performed.
EPCs from children with active vasculitis have decreased
colony-forming capacity
EPC-CFUs were reduced in 15 children with active vas-
culitis (median 6/well; range 1-16/well) compared to
healthy control children (median 16/well; range 4-21/
well), p = 0.02 and also (non-significantly) lower than
children with inactive vasculitis (median 13/well; range
4-15/well), p = 0.16 (Fig. 1b). There was no significant
difference in EPC-CFU among the five children with
inactive vasculitis compared to healthy child controls
(p = 0.3; Fig. 1b).
EPCs from children with active vasculitis demonstrate
decreased cluster formation on Matrigel
EPCs cultured for seven days were plated on Matrigel-
coated wells to assess EPC cluster formation (clusters of
EPCs containing more than ten cells), an inherent angio-
genic functional property of EPCs and a prelude to vascu-
lar sprouting (Fig. 2a, and insert). EPC cluster formation
was significantly lower in 15 children with active vasculitis
(median 738/mm2; range 0–2,813) compared to five
healthy control children (median 2,386 /mm2; range
1,522–2,652); p = 0.01 and also lower (non-significantly)
Table 1 Patient characteristics, baseline laboratory parameters,
circulating endothelial cell counts and treatment in 20 children
with systemic vasculitis
Demographic data Active PSV (n = 15) Inactive PSV (n = 5)
Median age, years (range) 12 (7–16.5) 12 (9–11.6)
Sex M/F 5 M:10 F 1 M:4 F
Classification n = 8 PAN; n = 4 GPA;
n = 1 EGPA; n = 1 KD;
n = 1 unclassified SV
n = 4 GPA; n = 1
Behçet’s disease
ESR, mm/h (median, range) 73 (11–137) 3 (3–37)
CRP, mg/L (median, range) 18.5 (5–270) 5 (5–16)
CEC count, cells/ml
(median, range)
88 (8–420) 16 (0–40)
Treatment (n)
Cyclophosphamide 5 2
Corticosteroids 11 3
MMF 1 2
Azathioprine 0 1
Colchicine 0 1
Rituximab 1 0
Classification of the vasculitic syndromes was based on the recent EULAR/
PRINTO/PRES classification criteria for pediatric vasculitis [19]. KD was
identified based on five of six of the American Heart Criteria.
Immunomagnetic bead extraction was used for enumeration of circulating
endothelial cells (CEC). Treatments summarised were received at any point of
the patients’ disease course. PAN polyarteritis nodosa, KD Kawasaki disease,
GPA granulomatosis with polyangiitis, EGPA eosinophilic granulomatosis with
polyangiitis, ESR erythrocyte sedimentation rate, CRP C-reactive protein, MMF
mycophenolate mofetil
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than children with inactive vasculitis (median 1,295 /mm2;
range 100–2,955; p = 0.31; Fig. 2b). There was no signifi-
cant difference in EPC cluster formation between children
with inactive vasculitis and healthy controls (p = 0.33).
EPCs from children with active vasculitis demonstrate
decreased incorporation into HUVEC networks
We next performed a Matrigel assay to investigate the
ability of EPCs to incorporate into HUVEC vascular net-
works. Co-culture of EPCs (from systemic vasculitis pa-
tients or healthy controls) and HUVECs on Matrigel led
to the formation of vascular tubule networks (Fig. 2c
and d). However, as summarised in Fig. 2e, the number
of EPC incorporated into HUVEC vascular networks on
Matrigel was decreased for 15 children with active vasculitis
(median 795/mm2; range 0-2,235/mm2; p = 0.003) and five
children with inactive vasculitis (median 814/mm2; 596-
2,500/ mm2; p = 0.04), compared to five healthy control
children (median 2,500/mm2; range 1,478-4,478/mm2).
TNF-α reduces EPC incorporation into HUVEC networks
We next assessed the effect of TNF-α on the function of
EPCs, since this inflammatory cytokine has been impli-
cated in the pathogenesis of many forms of SV in children
and adults [30, 31]. EPC were pre-treated with 10 ng/ml
TNF-α for three days of EPC culture, then EPC were col-
lected and the Matrigel assay was performed. The numbers
of EPC incorporated into HUVEC vascular networks, and
EPC clusters on Matrigel were significantly reduced after
pre-treatment with TNF-α (p = 0.02 and p = 0.008, respect-
ively, Fig. 3a and b). In contrast, TNF-α (10–100 ng/ml)
increased tube formation of HUVECs, similar to the effect
of VEGF, an effect that was blocked by 10 μg/ml infliximab
(a chimeric monoclonal antibody against TNF-α; data not
shown).
TNF-α reduces EPC adhesion by decreasing CD18/CD11b
expression
We then examined whether the inhibitory effect of TNF-α
on EPC vasculogenesis was due to alteration of the adhe-
siveness of cultured human EPCs to the activated endothe-
lial cells and/or the extracellular matrix. EPCs were again
pre-treated with 10 ng/ml TNF-α for three days, detached
Fig. 2 Reduced incorporation of endothelial progenitor cells (EPCs) into endothelial capillary network and cluster formation on Matrigel in children with
systemic vasculitis. a Representative image of EPC cluster formation on Matrigel. The inset shows an example of a sprouting EPC. b and c Representative
images of the incorporation of EPCs from a healthy child (b), and a child with active granulomatosis with polyangiitis (c) into an endothelial capillary
network on Matrigel. d Comparison of the number of EPC clusters with active and inactive systemic vasculitis and child healthy controls. The number of
EPC clusters was reduced for 15 children with active disease compared with healthy control children (p = 0.01); cells clusters in the inactive vasculitis
group did not differ significantly from healthy controls. e EPC incorporation into HUVEC capillary networks on Matrigel in children with active
and inactive systematic vasculitis and child healthy controls. Compared to five healthy control children, the number of EPC incorporated into
HUVEC vascular networks on Matrigel was decreased for 15 children with active vasculitis (p = 0.003) and five children with inactive vasculitis
(p = 0.04). The Kruskal-Wallis test was used to examine overall differences between the study groups followed by the Mann–Whitney U test.
P values <0.05 were considered significant. HUVEC human umbilical vein endothelial cell
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with 0.25 % trypsin, and then re-plated onto fibronectin-
coated dishes or HUVEC monolayers. EPCs pre-treated
with TNF-α exhibited a significant decrease in the number
of adhesive cells at 60 min compared with control (Fig. 3c):
adhesion to fibronectin at baseline 120 ± 50 versus 44.7 ±
17.9 post exposure to TNF-α; p = 0.02 and adhesion to ac-
tivated HUVEC monolayers at baseline 152.7 ± 10.5, versus
118.7 ± 17.4 after TNF-α, p = 0.04.
Since EPCs are known to migrate to, and accumulate at,
the site of tissue injury where they express complementary
sets of surface receptors (CD11b/CD18, CD54) that could
influence adhesion at these sites [32], using flow cytometry
we next investigated whether TNF-α would alter the ex-
pression of these surface receptors on EPC. Pre-treatment
with TNF-α down regulated the expression of CD11b
(Fig. 3d), but increased that of CD54, and had no effect on
CD146 or CD34 (data not shown).
Prolonged hyperthermia impairs HUVEC angiogenesis
and reduces EPC cluster formation
Sustained/prolonged pyrexia is an important clinical fea-
ture of virtually all chronic inflammatory diseases, includ-
ing SV. We therefore investigated the influence of
hyperthermia on HUVEC vascular network formation and
EPC cluster formation. HUVECs were initially incubated
in Matrigel for 60 min at 37 °C to allow their adhesion,
followed by exposure to hyperthermia (39 °C) for 2–18 h.
As shown in Fig. 4a, prolonged exposure to hyperthermia
resulted in a significant decrease in HUVEC tube forma-
tion at 4 and 18 h. DiI-labeled EPCs plated on Matrigel at
39 °C for 2–18 h demonstrated decreased cluster forma-
tion by 4 h (Fig. 4b). To investigate whether these effects
were the result of hyperthermia-induced cytotoxicity, we
evaluated HUVEC and EPC viability after exposure to
hyperthermia using a colorimetric assay; EPC or HUVECs
Fig. 3 The effect of tumour necrosis factor (TNF-α) on EPC vasculogenesis, adhesion and CD11b expression. EPCs were pre-treated with 10 ng/ml
TNF-α for three days before plating for the Matrigel assay to study the chronic effect of TNF-α on EPC function. a and b Comparison of EPC with/
without pre-treatment of TNF-α on cluster formation (a) and incorporation into HUVEC capillary networks (b) on Matrigel. The numbers of EPC clusters
(a) were lower after pre-treatment with TNF-α (p= 0.008). EPC incorporation into HUVEC vascular networks on Matrigel (b) was also significantly reduced
after pre-treatment with TNF-α (p = 0.02). c Effect of TNF-α on EPC adhesion to fibronectin or monolayers of activated HUVECs. EPCs were labeled with
Dil-I-LDL and allowed to adhere for one h to fibronectin or a monolayer of TNF-α-activated HUVECs. Pretreatment with TNF-α resulted in significantly
reduced EPC adherence to fibronectin (p = 0.02) or activated HUVEC monolayers (pretreated with TNF-α 50 ng/ml for six h; p = 0.04). d Representative
flow cytometric profile of CD11b expression by EPC after pretreatment with TNF-α 10 ng/ml for three days (thick black tracing) compared with control
(no TNF-α pre-treatment; broken tracing). EPC endothelial progenitor cells, HUVEC human umbilical vein endothelial cell
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incubated under heat at different time points did not ex-
hibit signs of increased cell death (Fig. 4c).
Discussion
In this study we demonstrated impaired endothelial repair
capacity of EPC in children with SV. Using in vitro assays
recapitulating in vivo morphogenesis events we have
shown that EPC adherence, colony formation, and integra-
tion into endothelial networks were significantly impaired
in children with active SV compared to patients with in-
active vasculitis and healthy child controls. Our findings
could suggest an impairment of endothelial repair capacity.
As in adults with SV and other vascular disorders, it would
be important to understand if this impaired endothelial re-
pair response could contribute to cardiovascular sequelae.
Despite the lack of a consensus definition for an EPC
[33], alterations in EPC biology have been linked to sev-
eral human illnesses associated with cardiovascular mor-
bidity and risk [34, 35]. Very little is currently known
about EPC biology in patients with SV, although studies
suggest that chronic inflammatory autoimmune diseases
including rheumatoid or psoriatic arthritis [36], systemic
lupus erythematosus [6, 37], and systemic sclerosis [38]
(amongst others) are associated with impairment in EPC
function that could contribute to the excessive cardio-
vascular morbidity associated with these diseases. In SV,
non-specific effects of chronic inflammation including
pro-inflammatory cytokine milieu [39] and sustained
pyrexia [40] could influence EPC biology in an adverse
way, particularly when associated with other factors associ-
ated with the burden of these diseases such as uraemia
Fig. 4 Effect of hyperthermia on endothelial progenitor cell (EPC) vasculogenesis, human umbilical vein endothelial cell (HUVEC) tube formation,
and viability. After EPC or HUVECs were plated on Matrigel for 1 h, cells were cultured at 39 °C for 2–18 h; after 2, 4 and 18 h, EPC clusters and
HUVEC tube branches were counted in 5/x100 fields, and the percentage of EPC clusters and tube formation (compared to control) was plotted
for each time point. a Hyperthermia inhibited HUVEC tube formation and b EPC cluster formation on Matrigel. c-f Representative images of HUVEC
capillary networks and EPC cluster formation on Matrigel at different temperatures. c HUVEC network at 37 °C. Exposure to 39 °C for 4 h inhibited HUVEC
capillary network formation (d). e EPC cluster formation on Matrigel at 37 °C was also reduced by incubation at 39 °C for 4 h (f). g Effect of hyperthermia
on cell viability. Cell viability was measured by XTT assay 2-18 h after heating. Cell viability of untreated cells is assumed as 100 %. Incubation at 39 °C at
2, 4 and 18 h did not cause cell death. All data represent the mean ± SD of three experiments. Statistical differences between heat treatment and control
were determined by two-way analysis of variance (ANOVA), followed by paired two-tailed T-test. ∗= P < 0.05; ** = P< 0.01. XTT xylin tetrazolium
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[41], hypertension [42], dyslipidaemia [43], and impaired
glucose tolerance [44]. Since a hallmark of SV is inflamma-
tion targeting endothelial cells, irrespective of the cause,
impairment of EPCs may be of particular importance clin-
ically since this would contribute further to an unfavour-
able balance between endothelial injury and repair.
Studies of EPCs in adults with SV relate mainly to anti-
neutrophil cytoplasmic autoantibody (ANCA) associated
vasculitis (AAV), and so far have provided apparently con-
flicting results, probably the result of patient and meth-
odological heterogeneity and/or differences in treatment.
Holmen et al. demonstrated that the numbers of EPC-
CFU were significantly decreased during active GPA as
compared with remission, and suggested that impairment
of EPC function was mediated in part by what they re-
ferred to as inflammatory circulating endothelial cells [45].
In contrast, De Groot et al. demonstrated no significant
difference in circulating CD34+ haematopoietic stem cells
and EPC-CFU numbers in patients with active AAV com-
pared with healthy control levels [46]. Both these EPC pa-
rameters, however, increased after the institution of
immunosuppressive therapy and disease remission in
GPA patients. Závada et al. confirmed the observation of
Holmen et al. of low EPC-CFU in adults with AAV, par-
ticularly in uraemic patients; but in contrast to the study
of de Groot et al. found that neither institution of treatment
nor entering remission increased the number of EPC-CFU
[47]. In a separate study the same group went on to dem-
onstrate that patients with AAV who had low EPC-CFU at
first presentation had significantly higher rates of early dis-
ease relapse, for the first time suggesting that EPC levels
might be important prognostically in AAV [48].
Only two studies have examined changes in EPCs in
children with vasculitis [16, 49]. In contrast to adults
with AAV, we have previously shown that children with
active SV respond to endothelial injury by release of
CD34 + CD133 + KDR+ EPCs into the circulation, pos-
sibly as an adaptive response to endothelial injury caused
by vasculitis [16]. This observation was consistent with
the findings of Nakatani et al. who observed a rise in cir-
culating CD34 + CD133+ EPCs in the sub-acute phase of
KD complicated by coronary artery lesions [49]. The
findings of our current study, however, emphasise that
CD34+ positive haematopoietic EPCs represent a differ-
ent cell population from the monocytic EPCs that un-
doubtedly represent the cells that form the colonies and
Matrigel clusters from PBMCs as defined in our present
study, and many other studies [33]. The present findings,
taken together with our previous studies [16, 18] suggest
that in children with active vasculitis there is an un-
favourable balance between endothelial injury and repair
since there is increased endothelial injury reflected by an
increase in CECs and EMPs and an additional disturb-
ance in cells efficient for repair.
Our data suggest that chronic inflammation per se could
account for impaired monocytic EPC function since we
established that both TNF-α and hyperthermia impaired
EPC function, in agreement with previous studies demon-
strating an adverse effect of TNF-α on EPC function in
adults with RA [50]. Indeed, there is also a considerable
amount of indirect evidence supporting a role of TNF-α in
the pathogenesis of systematic vasculitis [51–53]. As well
as confirming this adverse effect of TNF-α on EPCs, for
the first time we also demonstrated that TNF-α downregu-
lated the expression of CD11b on EPC, providing a mech-
anism for reduced adhesion of EPC into vascular
networks. This observation would not preclude alternative
mechanisms, such as accelerated EPC senescence, that
could also contribute to this EPC dysfunction [54–57].
Our findings have several implications. We now have
the unique ability to explore the endothelium non-
invasively, defining an imbalance between endothelial
damage and repair capacity for children with SV. This
multi-marker approach combining CEC, EMP and EPC
measurement provides novel insights into endothelial
dysfunction and moving forward could allow us to
explore the prognostic relevance of this approach in
individual patients studied longitudinally in multicentre
collaborative studies. Future therapeutic strategies aiming
to improve endothelial function, employing for instance
statins, ACE inhibitors or PPAR-gamma agonists (amongst
other potentially important drugs), could target the select-
ive reduction of endothelial injury and/or the promotion of
regenerative mechanisms, but ideally would address both
sides of the injury/repair equation. At the individual level,
such personalised therapeutic options could help reduce
late cardiovascular morbidity associated with childhood
vasculitis [13]. In that context it would be of considerable
interest to prospectively examine the influence of altered
endothelial repair responses in children with SV on late
structural arterial injury [13], an ongoing concern for sur-
vivors of other childhood vasculitides such as KD [58].
Our study has limitations. Systemic vasculitis is rare in
children and consequently the study population was
relatively small and heterogeneous; that said, we did not
observe any obvious difference in EPC function between
different forms of vasculitis in this study, and have previ-
ously demonstrated that downstream endothelial injury
processes are similar across different forms of paediatric
vasculitides [16, 18, 25, 59]. Additionally, the longitudinal
effect of treatment on EPC responses was not examined in
individual patients, but clearly it would be advantageous to
do so in the future. Other limitations relate to the poor
standardization of assays for EPCs, an inherent problem
for all studies of this nature. Methodological issues and
confusion created by the various definitions currently in
use remain a major cause of apparent conflicting results
regarding changes in EPC biology in human diseases.
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Standardisation of the methodology used to quantitate
EPCs including an exact and consensus definition for EPCs
is urgently needed to facilitate future studies [50].
Conclusions
In summary, two key findings from our study and previous
work in this area are: 1) circulating EPCs are increased in
response to active vasculitis in the young, a finding that
contrasts with adults with SV; and 2) EPC function (ex
vivo) is impaired. Whilst the clinical relevance of this ob-
servation remains undetermined, our findings could
indicate an impaired endothelial repair capacity that, in the
presence of ongoing endothelial injury, may further con-
tribute to endothelial dysfunction. Future studies are now
required to address the clinical implications of these obser-
vations in terms of late cardiovascular morbidity and the
influence of treatment on EPC biology in children with sys-
temic vasculitis.
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